GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Other Long-Term Liabilities

TG Therapeutics (FRA:NKB2) Other Long-Term Liabilities : €232.5 Mil (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Other Long-Term Liabilities?

TG Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2025 was €232.5 Mil.

TG Therapeutics's quarterly other long-term liabilities increased from Sep. 2024 (€-0.0 Mil) to Dec. 2024 (€-0.0 Mil) and increased from Dec. 2024 (€-0.0 Mil) to Mar. 2025 (€232.5 Mil).

TG Therapeutics's annual other long-term liabilities declined from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€-0.0 Mil) but then increased from Dec. 2023 (€-0.0 Mil) to Dec. 2024 (€-0.0 Mil).

TG Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for TG Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Other Long-Term Liabilities Chart

TG Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TG Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 232.48

TG Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

TG Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Other Long-Term Liabilities
Comparable Companies
LEGN NUVL IONS AXSM MDGL ADMA BBIO BPMC JAZZ HALO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TGTX:USA NKB2:Germany
Address
3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
Website
https://www.tgtherapeutics.com
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines